2

After several decades marked by the absence of new effective therapeutic options other than cytotoxic chemotherapy, new therapies are currently revolutionizing the management of metastatic triple-negative breast cancer (mTNBC) and have been incorporated into the latest guidelines. Major advances in survival improvement include the addition of immunotherapy to first-line chemotherapy, as well as the introduction of PARP inhibitors for patients with germline BRCA1/2 mutation. The use of these therapies is dependent on the presence of predictive biomarkers for therapeutic efficacy, making ongoing research in this area essential for patient care. Moreover, the recent introduction of antibody-drug conjugates (most notably sacituzumab govitecan) is dramatically changing the therapeutic landscape for this disease. New molecules targeting other tumors, as well as other combined chemotherapies, will soon be available in clinical practice, offering renewed hope (at last) for improving the prognosis of these aggressive forms of cancer.